公开(公告)号：US20240269133A1

公开(公告)日：2024-08-15

申请号：US18561405

申请日：2022-05-20

申请人： Purdue Pharma L.P.

发明人： Garth WHITESIDE ,  Stephen HARRIS

IPC分类号： A61K31/498 ,  A61K31/137 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/46 ,  A61K31/4725 ,  A61P13/10

CPC分类号： A61K31/498 ,  A61K31/137 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/46 ,  A61K31/4725 ,  A61P13/10

摘要： The disclosure provides a method of treating interstitial cystitis/bladder pain syndrome in a human subject in need of such treatment, comprising administering to the human subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In certain embodiments, the method comprises administering the compound of formula (IA).

公开(公告)号：US20240269082A1

公开(公告)日：2024-08-15

申请号：US17936940

申请日：2022-09-30

申请人： Purdue Pharma L.P.

发明人： Graeme DONNELLY ,  Sailaja BHASKAR

IPC分类号： A61K9/50 ,  A61K31/4458 ,  A61P25/00

CPC分类号： A61K9/5078 ,  A61K9/5026 ,  A61K9/5036 ,  A61K9/5073 ,  A61K31/4458 ,  A61P25/00

摘要： There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.

公开(公告)号：US20240261265A1

公开(公告)日：2024-08-08

申请号：US18404810

申请日：2024-01-04

申请人： Purdue Pharma L.P.

发明人： Thomas Jorg Mehrling

IPC分类号： A61K31/4184 ,  A61K31/337 ,  A61K33/243 ,  A61P35/00

CPC分类号： A61K31/4184 ,  A61K31/337 ,  A61K33/243 ,  A61P35/00

摘要： There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of ovarian cancer in a patient in need thereof.

公开(公告)号：US20240226019A1

公开(公告)日：2024-07-11

申请号：US18603884

申请日：2024-03-13

申请人： PURDUE PHARMA L.P. ,  PURDUE PHARMACEUTICALS L.P.

发明人： William H. MCKENNA ,  Richard O. MANNION ,  Edward P. O'DONNELL ,  Haiyong H. HUANG

IPC分类号： A61K9/28 ,  A61J3/00 ,  A61J3/06 ,  A61J3/10 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/24 ,  A61K31/485 ,  A61K45/06 ,  A61K47/10 ,  A61K47/34 ,  B29B7/02 ,  B29B7/88 ,  B29C35/04 ,  B29C35/16 ,  B29C37/00 ,  B29C43/00 ,  B29C43/02 ,  B29C43/52 ,  B29C71/00 ,  B29K71/00 ,  B29K105/00 ,  B29L31/00

CPC分类号： A61K9/28 ,  A61J3/005 ,  A61J3/06 ,  A61J3/10 ,  A61K9/0002 ,  A61K9/0053 ,  A61K9/1641 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/209 ,  A61K9/2095 ,  A61K9/284 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/2893 ,  A61K31/485 ,  A61K45/06 ,  A61K47/10 ,  A61K47/34 ,  B29B7/02 ,  B29B7/88 ,  B29C35/045 ,  B29C35/16 ,  B29C37/0025 ,  B29C43/003 ,  B29C43/02 ,  B29C43/52 ,  B29C71/00 ,  B29C71/009 ,  A61K9/2072 ,  B29C2035/046 ,  B29C2035/1658 ,  B29K2071/02 ,  B29K2105/0035 ,  B29K2105/251 ,  B29K2995/0088 ,  B29L2031/753

摘要： The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

公开(公告)号：US11918558B2

公开(公告)日：2024-03-05

申请号：US17730276

申请日：2022-04-27

申请人： Purdue Pharma L.P.

发明人： Thomas Jorg Mehrling ,  Marco Herling

IPC分类号： A61K31/4184 ,  A61K9/00 ,  A61P35/02

CPC分类号： A61K31/4184 ,  A61K9/0019 ,  A61P35/02

摘要： T-PLL Therapy There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.

公开(公告)号：US11911512B2

公开(公告)日：2024-02-27

申请号：US18096686

申请日：2023-01-13

申请人： Purdue Pharma L.P.

发明人： Haiyong Hugh Huang

IPC分类号： A61K9/20 ,  A61K9/24 ,  A61K31/485 ,  A61K9/00 ,  A61K9/28

CPC分类号： A61K9/2077 ,  A61K9/0053 ,  A61K9/209 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/28 ,  A61K31/485

摘要： In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.

公开(公告)号：US11896583B2

公开(公告)日：2024-02-13

申请号：US16621893

申请日：2018-06-13

申请人： EURO-CELTIQUE S.A.

发明人： Thomas Jorg Mehrling

IPC分类号： A61K31/4184 ,  A61P35/00 ,  A61K33/243 ,  A61K31/337

CPC分类号： A61K31/4184 ,  A61K31/337 ,  A61K33/243 ,  A61P35/00

摘要： There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of ovarian cancer in a patient in need thereof.

公开(公告)号：US20230301921A1

公开(公告)日：2023-09-28

申请号：US18096686

申请日：2023-01-13

申请人： Purdue Pharma L.P.

发明人： Haiyong Hugh Huang

IPC分类号： A61K9/20 ,  A61K9/24 ,  A61K31/485 ,  A61K9/00 ,  A61K9/28

CPC分类号： A61K9/2077 ,  A61K9/0053 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/28 ,  A61K31/485

摘要： In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.

公开(公告)号：US20230277507A1

公开(公告)日：2023-09-07

申请号：US18108736

申请日：2023-02-13

申请人： Purdue Pharma L.P.

发明人： Thomas Jorg Mehrling

IPC分类号： A61K31/4184 ,  A61P35/00 ,  A61N5/10

CPC分类号： A61K31/4184 ,  A61P35/00 ,  A61N5/10

摘要： There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcomain a patient in need thereof.

公开(公告)号：US20230134700A1

公开(公告)日：2023-05-04

申请号：US17892553

申请日：2022-08-22

申请人： PURDUE PHARMA L.P. ,  PURDUE PHARMACEUTICALS L.P.

发明人： William H. MCKENNA ,  Richard O. MANNION ,  Edward P. O'DONNELL ,  HAIYONG H. HUANG

IPC分类号： A61K9/28 ,  A61K9/20 ,  A61K9/16 ,  A61J3/06 ,  A61K9/00 ,  A61K31/485 ,  A61K47/34 ,  A61K9/24 ,  A61K45/06 ,  A61K47/10 ,  A61J3/10 ,  B29C43/00 ,  A61J3/00 ,  B29C37/00 ,  B29C43/52 ,  B29B7/88 ,  B29C35/04 ,  B29B7/02 ,  B29C35/16 ,  B29C43/02 ,  B29C71/00

摘要： The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.